$DRTS

JPMorgan upgraded Mercury Systems (MRCY) to Overweight with a $102 target, citing Q3 performance. Republic Services (RSG) was upgraded to Overweight with a $295 target, expecting positive waste volume growth in 2027. Raymond James upgraded Liquidia (LQDA) to Strong Buy with a $77 target, citing strong demand and legal settlement. Piper Sandler upgraded Alpha Tau (DRTS) to Overweight with a $22 target, highlighting its technology.

Piper Sandler upgraded Alpha Tau Medical to Overweight from Neutral and raised its price target to $22 from $8, a 175% increase. This implies a 99.5% downside from the Nov 11 close of $4515.

Analysts made notable calls on Nvidia (downgraded by Baird), Apple (neutral reiterated by UBS), CoreWeave (buy reiterated by Goldman Sachs), and others. Key points include Nvidia's delayed data center forecasts, Apple's lower iPhone wait times, and CoreWeave's potential for outsized returns. Other companies mentioned include Alpha Tau Medical, Republic Services, CareDx, Mentari, Unilever, Mercury Systems, Teradyne, FormFactor, Corning, Cognex, Littelfuse, and Zebra Technologies.

Alpha Tau Medical Ltd. (Nasdaq: DRTS, TASE: דרטס) will be added to the TA-90 and TA-125 indices of the Tel Aviv Stock Exchange (TASE) on Nov. 5, 2026. The company, which develops cancer therapy Alpha DaRT, expects increased visibility and liquidity. Its shares are dual-listed on Nasdaq and TASE.

Alpha Tau Medical Ltd. (DRTS) announced FDA approval to expand its REGAIN trial for recurrent glioblastoma to 20 patients, adding new endpoints. The company will present trial data at the 2026 Society for Neuro-Oncology Annual Meeting, marking the trial's first scientific presentation. The expanded study includes progression-free survival and quality-of-life assessments.

Alpha Tau Medical (NASDAQ: DRTS) reported strong results from cancer trials, including a 100% response rate in head and neck cancer and promising data in brain and pancreatic cancers. The company expects key data readouts in late 2026 and early 2027, which could impact its trajectory. Alpha Tau has $104.8 million in cash and a U.S. commercialization partnership with Tolmar.

Pro-Dex (PDEX) rose 18% to $77 on FY'26 results, with net sales up 16% to $77.5M. Odyssey (ODTX) gained 8% to $29.05, reporting a Q2 loss of $52.8M. Evolus (EOLS) climbed 2% to $9.31, with Q2 revenue up 21% to $84.1M. Biofrontera (BFRI) increased 6% to $1.63, with Q2 product revenue up 32.9%. Alpha Tau (DRTS) hit $15.17, reporting a Q2 loss of $68.8M.

Alpha Tau Medical (DRTS) completed enrollment in its IMPACT study for Alpha DaRT in pancreatic cancer treatment, expanding from 12 to 48 patients. The trial evaluates Alpha DaRT with chemotherapy, with initial results expected in early 2027. The company's stock closed at $14.11, down 3.62%, and was up 2.41% in pre-market trading.

Alpha Tau Medical Ltd. (DRTS) said it plans a dual listing, offering its ordinary shares on the Tel Aviv Stock Exchange (TASE) in addition to Nasdaq. The company filed registration documents to list outstanding and future shares, expected to trade on TASE under an English symbol DRTS. Management said the move targets Israeli investors and local-currency access. DRTS was up 2.7% at $13.50.

Alpha Tau Medical (DRTS) reported positive early clinical results for Alpha DaRT plus pembrolizumab (Keytruda) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma. In nine evaluable patients, the company said ORR was 100% with 44% complete responses and median overall survival of 18.2 months. DRTS shares closed at $13.47.